Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Distalmotion seeks FDA clearance for DEXTER use
Distalmotion has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to use the DEXTER …
-
Actinogen treats first patient in XanaMIA trial for Alzheimer’s
Actinogen has treated the first participant in the open-label extension (OLE) segment of its Phase IIb/III pivotal XanaMIA Alzheimer’s disease …
-
Biocytogen and Sihuan partner to advance new therapeutics for weight loss
Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss. Under …
-
MediBeacon secures CE Mark certification for TGFR monitor and sensor
MediBeacon has received the CE Mark certification under the European Union (EU) Medical Device Regulation (MDR) for its transdermal glomerular …
-
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa
AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Symeres and Ambagon collaborate for colorectal cancer molecules
Symeres has entered a collaboration with Ambagon Therapeutics on molecular glue research in colorectal cancer, aiming to address diseases considered …
-
Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
Abbott has announced the integration of its Precision Oncology portfolio into Flatiron Health's cloud-based electronic medical record (EMR) platform, OncoEMR. The …
-
Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial
Prilenia Therapeutics and Ferrer have enrolled the first participant in the pivotal Phase III PREVAiLS clinical trial assessing pridopidine in …
-
uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies
uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen …
-
FDA approves Anumana’s pulmonary hypertension algorithm
Anumana has received 510(k) clearance from the US Food and Drug Administration (FDA) for its ECG-AI pulmonary hypertension (PH) detection …
-
Lantern receives FDA clearance for paediatric STAR-001 CNS trial
Starlight Therapeutics' wholly owned subsidiary Lantern Pharma has secured the US Food and Drug Administration (FDA) clearance for its investigational …
-
Novo Nordisk receives FDA approval for basal insulin Awiqli
Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700 units/mL, a …
-
Neurophet and ALZ-NET sign MoU on Alzheimer’s therapies
South Korean AI company Neurophet has entered a memorandum of understanding (MoU) with the Alzheimer's Network for Treatment and Diagnostics …
-
myTomorrows and CUN partner on AI-assisted patient trial matching
Netherlands-based myTomorrows has entered a collaboration with Clínica Universidad de Navarra (CUN) to implement AI clinical trial matching, integrating into …
-
Simulations Plus and three pharma companies collaborate on AI-driven drug development
Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim …
